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ABSTRACT
Introduction Empiric data on indirect (herd) effects of 
pneumococcal conjugate vaccines (PCVs) in settings 
with low or heterogeneous PCV coverage are limited. The 
indirect effects of PCV, which benefits both vaccinated and 
non- vaccinated individuals, are mediated by reductions 
in vaccine- type (VT) carriage (a prerequisite for disease). 
The aim of this study among hospitalised children in Lao 
People’s Democratic Republic (Lao PDR) is to determine 
the effectiveness of a 13- valent PCV (PCV13) against VT 
pneumococcal nasopharyngeal carriage (direct effects) and 
the association between village- level PCV13 coverage and 
VT carriage (indirect effects).
Methods Pneumococcal nasopharyngeal carriage 
surveillance commenced in December 2013, shortly 
after PCV13 introduction (October 2013). We recruited 
and swabbed children aged 2–59 months admitted to 
hospital with acute respiratory infection. Pneumococci 
were detected using lytA quantitative real- time PCR and 
serotyped using microarray. PCV13 status and village- 
level PCV13 coverage were determined using written 
immunisation records. Associations between both PCV13 
status and village- level PCV13 coverage and VT carriage 
were calculated using generalised estimating equations, 
controlling for potential confounders.
Results We enrolled 1423 participants and determined 
PCV13 coverage for 368 villages (269 863 children 
aged under 5 years). By 2017, median village- level 
vaccine coverage reached 37.5%, however, the IQR 
indicated wide variation among villages (24.1–56.4). 
Both receipt of PCV13 and the level of PCV13 coverage 
were independently associated with a reduced odds of 
VT carriage: adjusted PCV13 effectiveness was 38.1% 
(95% CI 4.1% to 60.0%; p=0.032); and for each per 
cent increase in PCV13 coverage, the estimated odds of 
VT carriage decreased by 1.1% (95% CI 0.0% to 2.2%; 
p=0.056). After adjustment, VT carriage decreased from 
20.0% to 12.8% as PCV13 coverage increased from zero 
to 60% among under 5.
Conclusions Despite marked heterogeneity in PCV13 
coverage, we found evidence of indirect effects in Lao 
PDR. Individual vaccination with PCV13 was effective 
against VT carriage.
BACKGROUND
Pneumococcal disease is a leading cause of 
morbidity and mortality in children, with most 
cases occurring in low- income and middle- 
income countries (LMICs).1 The introduc-
tion of pneumococcal conjugate vaccines 
(PCVs) has reduced pneumococcal disease 
in many settings.2 3 The vaccines’ benefits 
have also extended to unvaccinated groups 
through indirect effects.4 This is achieved 
by the reduction of vaccine- type (VT) pneu-
mococcal carriage among vaccinated chil-
dren which interrupts transmission of pneu-
mococci to vaccinated and non- vaccinated 
contacts.5
Understanding indirect effects is vital as 
the cost- effectiveness of the vaccine greatly 
improves when the protection afforded to 
the unvaccinated population is considered.6 7 
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Furthermore, the potential role for a reduced- dose PCV 
schedule, once VTs are under control, is of great interest 
globally.8 Reduced dose schedules use two doses (eg, 1+1) 
rather than the standard three and therefore substan-
tially reduce programme costs. However, the success 
of a 1+1 schedule relies on sustained indirect effects to 
protect children who have only received one primary 
dose in infancy and therefore likely to have suboptimal 
direct protection during the time they are most at risk of 
disease.8 Therefore, being able to measure and monitor 
indirect effects in different settings is critical.
Measurement of PCV impact on disease is challenging 
and resource- intensive.9 Many LMICs are unable to 
conduct robust pneumococcal disease surveillance to 
monitor indirect effects, making it very difficult to eval-
uate the full benefit of PCV in their population.9 An 
alternative approach for assessing PCV impact is using 
surveillance of nasopharyngeal (NP) pneumococcal 
carriage.10 Pneumococcal carriage is common and gener-
ally asymptomatic.5 It is the primary means of pneu-
mococcal transmission and a prerequisite for invasive 
disease.5 PCVs reduce carriage of VTs in the nasopharynx 
among vaccinated individuals, thereby reducing trans-
mission and providing indirect effects to both vaccinated 
and non- vaccinated individuals.10
It is often assumed that high PCV coverage is required 
to interrupt VT pneumococcal transmission and achieve 
substantial indirect effects (or indeed the elimination 
of VT pneumococcal disease), since near- elimination 
has predominantly been demonstrated in countries 
with greater than 90% vaccine coverage.8 However, two 
observational studies from the USA suggest that statisti-
cally significant indirect effects against pneumococcal VT 
carriage can be achieved at 58%–75% coverage among 
children under 5 years of age,11 12 but evidence from 
LMICs are lacking.4
Measuring indirect effects is challenging. Since indi-
rect effects benefit both vaccinated and non- vaccinated 
people within a population, it is typically measured 
through comparisons pre- PCV and post- PCV introduc-
tion. However, these studies need to take into account 
extraneous factors which affect patterns of pneumo-
coccal carriage and disease over time, such as changes 
in smoking rates or prevalence of household crowding.13 
Furthermore, baseline data for comparisons pre- PCV 
and post- PCV may not always be available.10 In recogni-
tion of these limitations, a study from Bangladesh used 
a novel approach to assess the indirect effects of cholera 
vaccine which compared the rates of cholera in commu-
nities with varying levels of vaccine coverage.14 For this 
study, we adapted these methods to evaluate the direct 
and indirect effects of PCV.15
In October 2013, Lao People’s Democratic Republic 
(Lao PDR) became one of the first countries in South- 
East Asia to introduce PCV13 into their Expanded 
Programme of Immunisation programme using a 3+0 
schedule, supported by Gavi, the Vaccine Alliance. Lao 
PDR has a high child mortality rate,16 and pneumonia is 
estimated to account for 20% of both deaths and hospital-
isations in children 1–59 months of age.17 18 From cross- 
sectional carriage surveys pre- PCV and 2 years post- PCV 
in Lao PDR, there was some evidence of indirect effects 
following PCV13 introduction, with a reduction in the 
carriage of PCV13 serotypes (adjusted prevalence ratio 
(aPR) 0.74 (95% CI 0.43 to1.27)) among infants too 
young to be vaccinated, but the confidence intervals 
included the null value (ie, an aPR of 1.00).19
For this study, we hypothesised that an inverse asso-
ciation exists between village- level PCV13 vaccination 
coverage in children under 5 years old (the age group 
most responsible for transmission) and the risk of VT 
pneumococcal carriage among both vaccinated and 
Key questions
What is already known?
 ► There is ample evidence from high- income countries that pneumo-
coccal conjugate vaccines (PCVs) reduce the burden of pneumo-
coccal disease in vaccinated and unvaccinated populations through 
both direct and indirect (herd) effects. The indirect effects comprise 
a substantial component of overall vaccine impact, contributing to 
the cost- effectiveness of the vaccine. This evidence is largely based 
on data from invasive pneumococcal disease surveillance, which 
can be challenging to implement in resource limited settings that do 
not routinely collect blood or cerebrospinal fluid samples as part of 
clinical care, since surveillance requires large numbers of samples 
to detect a rare outcome.
 ► Pneumococcal carriage surveillance provides an alternative method 
that is well suited to monitoring indirect effects, since carriage is a 
prerequisite for disease and the indirect effects of PCV are medi-
ated by reductions in vaccine- type (VT) carriage and transmission.
What are the new findings?
 ► Our adjusted model predicts that in Lao People’s Democratic 
Republic (Lao PDR), the prevalence of VT carriage decreased 36%, 
from 20% to 12.8%, through increases in PCV13 coverage alone 
(from 0% to 60% among children under 5 years old). Individual vac-
cination further protects vaccinated individuals against VT carriage 
by 39.1%.
 ► Our findings challenge preconceptions that high PCV coverage is 
required for substantial indirect protection and suggests that sub-
stantial benefits can be observed with lower and heterogeneous 
PCV coverage.
What do the new findings imply?
 ► Using an innovative approach, we were able to generate robust es-
timates for both the direct and indirect effects of PCV13 against 
VT carriage in Lao PDR. This is one of the few studies using pneu-
mococcal carriage among hospitalised children with acute respira-
tory infection to evaluate PCV impact. Sampling children admitted 
to hospital allows countries to establish surveillance quickly in an 
accessible population.
 ► Our results have important implications for the applicability of 
reduced dose schedules in low coverage settings. Reduced dose 
schedules, comprising two rather than three or four doses, have 
the potential to substantially reduce PCV programme costs but rely 
on indirect effects to maintain vaccine impacts. Therefore, under-
standing the determinants of indirect effects in a range of settings 
is global research priority.
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undervaccinated children.20 To investigate this, we 
established pneumococcal NP carriage surveillance 
among children with acute respiratory infection (ARI), 
commencing alongside PCV13 introduction in Lao PDR. 
Therefore, in children hospitalised with ARI we aimed 
to: (1) describe trends in VT carriage over time following 
PCV13 introduction; (2) investigate the association 
between PCV13 coverage at each child’s village of resi-
dence with the VT carriage (ie, indirect effects) and (3) 
calculate the adjusted PCV13 vaccine effectiveness (VE) 
in the same population (ie, direct effects).
METHODS
Study setting
This study was conducted in Vientiane, the capital of 
Lao PDR, where 12.7% of the population resides.21 Lao 
PDR is divided into three administrative tiers: province, 
district and village. Participants were recruited at Mahosot 
Hospital, a tertiary referral central hospital located 
within Vientiane Province, which has nine districts, 
485 villages, and an average population of 1693 people 
per village, according to the 2015 census.22 PCV13 was 
introduced into the national immunisation programme 
in October 2013 using a 3+0 schedule, administered at 
6, 10 and 14 weeks of age.23 During the initial PCV13 
roll- out, there was a catch- up programme, comprised of 
a single dose, for infants up to 12 months of age. Immu-
nisations are administered at designated village health 
centres or district hospitals and recorded in both hand- 
written registers and the parent- held mother child health 
(MCH) cards. Vaccination coverage data are collated 
and reported to the Ministry of Health for routine moni-
toring of immunisation coverage.
Study design
In this observational study, we enrolled children 2–59 
months of age admitted with ARI and obtained an NP 
swab to detect pneumococcal carriage. This analysis was 
part of a multi- site study across the Asia- Pacific region 
examining the relationship between PCV13 coverage 
and indirect effects in Lao PDR, Mongolia and Papua 
New Guinea.9 The Lao PDR component was embedded 
within a prospective hospital- based study of the aetiology 
of ARI.23 We used the same terminology outlined by 
Halloran et al in which indirect effects are defined as the 
population- level effects of a vaccination strategy experi-
enced by individuals regardless of vaccination status.24
Participant recruitment
Between December 2013 and December 2019, study 
doctors recruited patients on weekdays from all paedi-
atric wards of Mahosot Hospital. Eligible participants 
were children aged 2–59 months with ARI—defined as 
fever (self- reported or documented >38.0°C) and one 
or more respiratory symptoms and signs including dysp-
noea, cough, rhinitis or abnormal pulmonary ausculta-
tory examination, with symptom onset within 14 days 
prior to admission. Children that did not satisfy the eligi-
bility criteria were excluded.
Following informed consent, NP samples were 
collected from cases using paediatric flocked swabs 
(Copan Diagnostics). Swab samples were stored in 
1 mL skim milk tryptone- glucose- glycerol media, then 
transported to the local laboratory for handling and 
storage according to WHO guidelines.25 The majority 
of swabs were collected within 24 hours of admission to 
hospital (with the exception of admissions from Friday 
to Saturday which might be delayed for 1–3 days, since 
recruitment was during weekdays only). Data on demo-
graphics, medical care and hospital admission outcomes 
were collected for each participant. Individual PCV13 
vaccination status was determined based on documented 
evidence of receiving an adequate number of PCV13 
doses at least 14 days before enrolment.26 To determine 
vaccination status, we checked the parent- held MCH 
card for recorded PCV13 dates of administration or, if 
these were not available, study staff contacted the child’s 
health centre. A participant was defined as vaccinated 
if they had received an adequate number of doses for 
immune protection that is, two or more PCV13 doses at 
less than 12 months of age, or at least one dose at or after 
12 months of age.11 Conversely, a participant was defined 
as ‘under- vaccinated’ if they had received less than the 
adequate number of PCV13 doses for immune protec-
tion, including those who had received no doses.11 For 
participants without written evidence of PCV13 status, 
we further classified them as under- vaccinated if parents 
verbally reported that the participant had not received 
any vaccines or if the participant was not age eligible to 
receive PCV13.
Participant data were double- entered using elec-
tronic databases (Microsoft Access and REDCap). 
Regular double- entry discrepancy and logic checks were 
conducted prior to analysis.
Village vaccination coverage
Village vaccination coverage data were also collected to 
address aims 2 and 3. Visits to health centres for data 
collection were organised based on a list of villages 
where participants resided for participants enrolled up 
to June 2017. Visits commenced in June 2017 and were 
completed in June 2018. Therefore, analyses for aims 2 
and 3 included all participants recruited up to June 2017 
and the additional 77 participants enrolled up to June 
2018 that resided in villages where vaccination data had 
already been collected. To determine the number of chil-
dren vaccinated for PCV13 in each village, we extracted 
and transcribed relevant data from register books into a 
study database. Written register books contain line- listed 
data for each child residing in the village and the dates 
vaccinations were administered. Study staff also provided 
qualitative assessment of vaccination coverage data 
quality. Data were categorised as high quality if PCV13 
dates were clearly identified and legible and registration 
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books were available. For more details see online supple-
mental appendix page 2.
For each participant, we determined the village- 
level PCV13 coverage at the time each participant was 
enrolled—defined as the number of children under 
5 years of age vaccinated in the participant’s village (at 
participant enrolment date) divided by the population 
of all children under 5 years of age in their village in 
2015 (approximately midpoint of study period). Vaccine 
coverage was calculated among children less than 5 years 
of age, which includes children ineligible for PCV13 by 
age, since this is a critical age group primarily respon-
sible for pneumococcal transmission.20 The number of 
children under 5 years of age living in each village was 
sourced from the health facility responsible for providing 
health services for each village. These population data 
were based on a government census conducted in 2015.22 
We excluded Sisattanak district in Vientiane Capital, 
which has a population of 11 069 children under 5 years, 
where immunisation records were recorded by dose 
rather than by child, therefore we were unable to deter-
mine how many children were vaccinated according to 
our study definitions.
Laboratory procedures
Samples were shipped on dry ice to the Murdoch Chil-
dren’s Research Institute, Melbourne, Australia for 
sample testing and analysis. Samples were screened for 
the presence of pneumococci using quantitative real- time 
PCR (qPCR) targeting the lytA gene.19 Samples that were 
lytA qPCR positive (Ct value <35) or equivocal (Ct value 
35–40) were cultured for molecular serotyping of pneu-
mococcal isolates by microarray. Samples with Ct >40.0 
were considered negative for pneumococcus. Molecular 
serotyping was performed using Senti- SP V.1.5 microarray 
(BUGS Bioscience) as previously described.27 28 Samples 
that were lytA qPCR positive (Ct value <35) but not 
able to be serotyped (either culture negative or due to 
repeated technical difficulties with DNA extraction) were 
considered pneumococcal positive, serotype unknown. 
Laboratory data were cleaned prior to analysis, including 
the removal of non- pneumococcal microarray calls. 
For more details on sample collection, transport, DNA 
extraction, lytA qPCR, culture and microarray methods, 
refer to previously published methods.19
As pneumococcal carriage prevalence and serotype 
distribution from hospital- based carriage surveillance 
may be affected by prior antibiotic use, we determined 
the presence of antimicrobial resistance (AMR) genes to 
enable comparison with other settings. The microarray 
detects 10 AMR genes associated with mobile genetic 
elements, encoding resistance to tetracycline (tetM, tetK, 
tetO, tetL), chloramphenicol (cat), macrolides (mefA, 
ermB, ermC), kanamycin (aphA3), streptothricin (sat4), 
lincosamides (ermB, ermC), and streptogramin B (ermB, 
ermC). As microarray currently provides a single overall 
AMR profile for all species detected, we restricted analysis 
to samples containing a single pneumococcal type with 
no other species identified, as per previous studies.19
Overall pneumococcal carriage was defined as detection 
of any pneumococcus in an NP swab sample (including 
samples that were lytA positive and culture negative 
(n=71) or were unable to be serotyped due to repeated 
technical difficulties with the DNA extraction (n=1)). 
VT carriage was defined as NP carriage of at least one 
pneumococcal serotype included in the PCV13 vaccine: 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 
23F. Samples were considered VT carriage positive if 
they contained at least one PCV13 serotype, regardless 
of any other serotypes present in the sample. Similarly, 
samples were considered non- VT carriage positive if they 
included at least one non- PCV13 serotype, regardless of 
any other serotypes present in the sample.
Analyses
Characteristics of all the participants enrolled up to 
December 2019 were summarised by percentages, or 
medians and IQRs, where appropriate. We compared 
study characteristics by PCV13 vaccination status to iden-
tify any differences between vaccinated and undervacci-
nated children, as well as those with missing vaccination 
status. To show trends in VT carriage among vaccinated 
and under- vaccinated children over time (aim 1), we calcu-
lated moving carriage prevalence rates within 7- month 
rolling intervals to smooth random variation due to small 
monthly sample sizes. We included all participants with 
data on PCV13 status and adjusted the carriage preva-
lence rates by age group (2–11 months, 12–23 months, 
24–59 months), using a direct adjustment method.29 We 
adjusted for age to account for random variation in the 
age of participants recruited each month, since age is a 
known determinant of pneumococcal carriage.
To describe the PCV13 coverage data, we tabulated 
the median village vaccination coverage by year. We also 
reported on the quality of vaccine coverage data by village. 
Annual village PCV13 coverage was mapped by coverage 
quintiles and an additional category for coverage above 
100% (0–19,20-39,40–59,60-79,80–99,100+%) for Vien-
tiane Province from 2014 to 2017 using QGIS V.3.8.30 
Village vaccine coverage can appear to exceed 100% due 
to inaccuracies in population denominators or if children 
from outside the catchment area have received vaccina-
tions at the health centre. Coverage data from 2018 were 
not mapped due to the small number of data points from 
seven villages only.
To examine the relationship between village- level 
PCV13 coverage and VT carriage (aim 2), we first calcu-
lated the PCV13 coverage in each participant’s village of 
residence on the date each participant was enrolled. To 
describe the data, we tabulated VT carriage prevalence 
among participants at quartiles of district- level PCV13 
coverage (at the time of each participants’ enrolment) 
stratified by vaccination status.
For both adjusted and unadjusted (‘crude’) analyses 
examining the relationship between PCV13 coverage and 
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VT carriage, we used generalised estimating equations 
with a binomial distribution, a logit link function and 
an exchangeable correlation structure, accounting for 
clustering at the village level, since participants from the 
same village are not independent. We included partici-
pants with complete data for all variables in the model 
(complete case analysis). We adjusted for PCV13 status, 
age in years, season (month of swab collection), monthly 
family income category (as a proxy for socioeconomic 
status), number of children under five in the household, 
and kindergarten attendance. These covariates were 
selected a priori using a directed acyclic graph, informed 
by relevant literature and refined through expert consul-
tation (online supplemental figure 1). The linearity 
assumption was assessed using a lowess plot.
In order to quantify the effect of PCV13 coverage 
on VT carriage prevalence, we estimated and graphed 
marginal mean VT carriage prevalence by decile of 
PCV13 coverage, accounting for the balance of the other 
covariates across all the individuals, using the margins 
and marginsplot commands in Stata. To act as a bias indi-
cator, we constructed an additional model with overall 
pneumococcal carriage as the outcome, since we do 
not expect that vaccine introduction will impact overall 
carriage prevalence. Many studies indicate that overall 
pneumococcal carriage remains constant following 
PCV introduction despite decreases in VT carriage due 
to corresponding increases in non- VT carriage preva-
lence.9 15
Since PCV13 status was included as a covariate in the 
model developed for aim 2, we were able use the same 
model output to calculate adjusted VE for aim 3. VE was 
calculated as one minus the the odds ratio of PCV13 
carriage in vaccinated versus undervaccinated children 
multiplied by 100.
For aims 2 and 3, sensitivity analyses were performed, 
excluding participants with low quality vaccination 
coverage data, to determine whether results were affected 
by data quality.
All analyses were undertaken using Stata V.15.31 The 
community- contributed command baselinetable was 
used to construct table 1.32
Sample size
The sample size calculation was based on our primary 
question regarding the association between village 
PCV13 coverage and the VT carriage (aim 2), and was 
previously published in our study protocol.9 Calcula-
tions were performed using nQuery Advisor+nTerim 
V.4.0. Calculations were based on sample size methods 
for logistic regression models with a continuous covar-
iate (ie, PCV13 coverage) and additional covariates, with 
inflation to account for clustering within villages (intr-
aclass coefficient of 0.1). At the mean level of PCV13 
coverage, we assumed a VT carriage prevalence of 30%, 
while at a coverage level one SD above the mean, we 
assumed VT carriage would decline to 20%. Assuming a 
significance level of 0.05, allowing for adjustment using 
multiple covariates with an R- squared value of 0.4, 600 




Between December 2013 and December 2019, 6413 chil-
dren were screened for eligibility. We enrolled 1493 and 
included 1 485 in our descriptive analyses of carriage 
trends over time (figure 1).
Table 1 summarises the characteristics of the study 
participants by PCV13 vaccination status. The percentage 
of missing data was less than 10% for all variables except 
PCV13 status (15% missing). The characteristics of those 
with missing PCV13 status were largely similar to the 
overall participant cohort, with minor differences in the 
percentage of participants with a smoker in the house, 
preadmission antibiotic use and AMR gene patterns. 
There were no differences in antibiotic use or the 
percentage of lytA positive samples that cultured pneu-
mococci by PCV13 vaccination status. There were minor 
differences in the other characteristics of participants 
based on their vaccination status (table 1), for example, 
level of maternal education, indicated by completion of 
primary school, was higher in vaccinated children (85.9%) 
compared with undervaccinated children (73.2%). VT 
carriage prevalence and percentage of pneumococcal 
single- serotype samples with at least one AMR gene were 
both lower among vaccinated participants.
Pneumococcal carriage
Among the 1485 participants, pneumococcal carriage 
prevalence was 35.8%. Eighty- seven per cent (462/532) 
of lytA positive samples were successfully cultured for 
pneumococci, of which 40.7% contained PCV13 sero-
types. The individual serotypes identified are graphed by 
year in online supplemental figure 2. AMR genes were 
common, with 74.4% of pneumococcal positive single- 
serotype samples containing at least one of the 10 AMR 
genes assessed. Overall carriage and AMR gene patterns 
were largely consistent over time and VT carriage preva-
lence decreased over time (table 2). There appeared to 
be an increase in the number of samples that were lytA 
positive and culture negative over time, which was not 
explained by changes in antibiotic usage or severity of 
illness among the participants over time (online supple-
mental table 1).
The adjusted monthly prevalence of VT carriage 
following PCV13 introduction is shown in figure 2. Over 
this period, the adjusted VT carriage rates declined in 
both vaccinated and under- vaccinated participants 
(figure 2).
PCV coverage
Vaccination and census data from 590 villages, 
comprising 1 549 534 children under 5 years of age, 
were collected. Vaccination coverage data were assessed 
as high quality for 69 villages (11%), with PCV13 clearly 
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Table 1 Participant characteristics by 13- valent pneumococcal conjugate vaccine (PCV13) status, Lao PDR, December 
2013–June 2019
Total





N=1485* N=492 N=757 N=236
Median age in months, (IQR) 15.0 (8.0–26.0) 18.0 (6.0–32.0) 14.0 (9.0–22.0) 18.0 (9.0–27.0)
Age group, n (%)
  2–11 months 590 (39.7) 198 (40.2) 314 (41.5) 78 (33.1)
  12–35 months 466 (31.4) 102 (20.7) 285 (37.6) 79 (33.5)
  36–59 months 429 (28.9) 192 (39.0) 158 (20.9) 79 (33.5)
Male, n (%) 825 (55.6) 261 (53.0) 441 (58.3) 123 (52.1)
Year of enrolment, n (%)
  2013‡ 6 (0.4) 4 (0.8) 2 (0.3) 0 (0.0)
  2014 353 (23.8) 219 (44.5) 105 (13.9) 29 (12.3)
  2015 321 (21.6) 113 (23.0) 162 (21.4) 46 (19.5)
  2016 286 (19.3) 73 (14.8) 155 (20.5) 58 (24.6)
  2017 229 (15.4) 36 (7.3) 145 (19.2) 48 (20.3)
  2018 164 (11.0) 33 (6.7) 109 (14.4) 22 (9.3)
  2019 126 (8.5) 14 (2.8) 79 (10.4) 33 (14.0)
Wet season, n (%) 748 (50.4) 252 (51.2) 365 (48.2) 131 (55.5)
Urban§, n (%) (N=1482) 1413 (95.3) 465 (94.5) 731 (96.9) 217 (91.9)
Kindergarten attendance, n (%) (N=1477) 329 (22.3) 113 (23.3) 150 (19.8) 66 (28.1)
Median no of other children <5 years in 
house, (IQR) (N=1476)
1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Family income per month, n (%) (N=1476)
  ≤₭250 000 74 (5.0) 47 (9.6) 20 (2.7) 7 (3.0)
  ₭250 001–₭1 000 000 kip 301 (20.4) 155 (31.6) 109 (14.5) 37 (15.9)
  ₭1 000 001–₭3 000 000 591 (40.0) 201 (41.0) 294 (39.0) 96 (41.4)
  ₭3 000 001–₭5 000 000 380 (25.7) 69 (14.1) 245 (32.5) 66 (28.4)
  >₭5 000 000 130 (8.8) 18 (3.7) 86 (11.4) 26 (11.2)
Maternal education (completion of 
primary school), n (%) (N=1345)
1083 (80.5) 342 (73.2) 577 (85.9) 164 (79.6)
Piped water source, n (%) (N=1483) 843 (56.8) 245 (49.8) 467 (61.8) 131 (55.7)
Wood or charcoal used for cooking fuel, n 
(%) (N=1178)
1029 (87.4) 248 (81.8) 597 (89.6) 184 (88.0)
Smoker in the house, n (%) (N=1471) 632 (43.0) 200 (41.6) 321 (42.5) 111 (47.2)
Pneumonia categories, n (%)¶ (N=1467)
  Acute respiratory infection
  (not pneumonia)
574 (39.1) 180 (36.9) 298 (39.8) 96 (41.7)
  Pneumonia (not severe) 417 (28.4) 127 (26.0) 222 (29.6) 68 (29.6)
  Severe pneumonia 476 (32.4) 181 (37.1) 229 (30.6) 66 (28.7)
Pre- admission antibiotics**, n (%) 
(N=1432)
766 (53.5) 264 (55.6) 397 (54.0) 105 (47.3)
Received antibiotics in hospital, n (%) 
(N=1453)
1266 (87.1) 430 (88.8) 638 (86.1) 198 (86.8)
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marked and dates being legible for 189 villages (32%) 
and no evidence of missing vaccination books for 456 
villages (77%). From 2014 to 2017, the median PCV13 
coverage among all villages (excluding Sisattanak district) 
increased from 4.5% to 37.5% among children under 
5 years (online supplemental tables 2 and 3). Figure 3 
shows the heterogeneity in coverage among children 
under five in each participant’s village within Vientiane 
Capital. Maps of village level PCV13 coverage for partici-
pants from outside of Vientiane Capital are presented in 
online supplemental figure 3.
Association between PCV13 coverage and VT carriage
VT carriage prevalence among participants stratified by 
levels of PCV13 coverage indicated an inverse relation-
ship between PCV13 coverage and VT carriage among 
under- vaccinated participants (table 3). Analyses were 
based on 845 participants from 368 villages, with a popu-
lation of 269 863 children under five years of age.
From the adjusted analyses, for each increase in 
percentage point of PCV13 coverage, the estimated odds 
of VT carriage decreased by 1.1% (95% CI 0.0% to 2.2%; 
p=0.056) (table 3). As expected, there was no evidence 
of an association between PCV13 coverage and overall 
pneumococcal carriage after adjustment (OR 0.998 (95% 
CI 0.991 to 1.004); p=0.475) (table 4). The predicted 
probability of VT carriage at each decile of village PCV13 
coverage up to 60% is shown in figure 4. We estimated 
up to 60% coverage, since there were few participants 
from villages with greater than 60% coverage among 
children under five. As PCV13 coverage increased from 
zero to 60%, VT carriage prevalence reduced by 36%, 
from 20.0% (95% CI 15.2% to 24.9%) to 12.8% (95% 
CI 8.5% to 17.1%). From this model, which includes 
PCV13 status, the adjusted VE was 38.1% (95% CI 4.1 to 
60.0; p=0.032) against VT carriage, adjusting for PCV13 
coverage (indirect effects), family income, age, season, 
number of children under five in the household and 
kindergarten attendance. The sensitivity analysis which 
excluded participants from villages with poor quality 
vaccination coverage data found similar effect sizes for 
both direct and indirect effects of PCV13 (online supple-
mental table 4).
DISCUSSION
Using a novel approach, our study is the first to show 
substantial indirect effects on pneumococcal VT carriage 
in a setting with moderate and heterogeneous PCV13 
coverage. We estimated a 36% reduction in VT carriage 
through indirect effects alone up to 5 years following 
PCV13 introduction, as coverage increased from zero 
to 60%. We expect that reductions in VT carriage in 
Lao PDR will equate to reductions in VT disease, since 
carriage is a prerequisite for disease.5 Our findings 
are consistent with recent community carriage surveys 
Total





N=1485* N=492 N=757 N=236
Pneumococcal carriage prevalence††, n 
(%)
532 (35.8) 180 (36.6) 261 (34.5) 91 (38.6)
Vaccine- type pneumococcal carriage 
prevalence††, n (%) (N=1415)
188 (13.3) 87 (18.8) 70 (9.6) 31 (13.7)
Non- vaccine- type pneumococcal carriage 
prevalence††, n (%) (N=1415)
302 (21.3) 77 (16.7) 170 (23.4) 55 (24.3)
Percentage of lytA positive samples, 
serotype unknown‡‡, n (%) (N=532)
462 (86.8) 150 (83.3) 231 (88.5) 81 (89.0)
Percentage of pneumococcal single- 
serotype samples with at least one AMR 
gene, n (%) (N=394)
293 (74.4) 100 (78.7) 137 (69.2) 56 (81.2)
*N=1485 unless otherwise specified in the first column.
†Undervaccinated defined as less than one dose received under 12 months of age and no doses ≥12 months of age.
‡Recruitment started in December 2013.
§Categorised as urban if the village falls within Vientiane Capital.
¶WHO 2013 definition.
**Parent report.
††Pneumococcal carriage was defined as detection of any pneumococcus, including samples that were lytA positive and serotype unknown. 
However, lytA positive samples with an unknown serotype were excluded from VT and NVT carriage prevalence estimates.
‡‡Serotypes were either unknown due to the sample being culture negative (n=71) or unable to be serotyped due to repeated technical 
difficulties with the DNA extraction (n=1)).
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conducted in Lao PDR which found reductions, although 
non- statistically significant, in VT carriage among infants 
too young to be vaccinated only 2 years following PCV 
introduction (ie, indirect effects).33 Our results are also 
in line with previous studies from the USA, reporting that 
moderate coverage among children under 5 years of age 
Figure 1 Flow chart of study recruitment at Mahosot Hospital, Lao PDR, December 2013–June 2019. *Final rounds of 
vaccine coverage data collection for PCV13 vaccination coverage were conducted up to June 2018. Lao PDR; Lao People’s 
Democratic Republic; PCV; pneumococcal conjugate vaccine.
Table 2 Characteristics of pneumococcal carriage samples by year, Vientiane, Lao PDR, December 2013–June 2019
2013–2014 2015 2016 2017 2018 2019
Pneumococcal carriage 
prevalence*, n/N (%)
156/359 (43.5) 117/321 (36.4) 90/286 (31.5) 81/229 (35.4) 42/164 (25.6) 47/126 (37.3)
Vaccine- type (VT) 
pneumococcal carriage 
prevalence*, n/N (%)
81/344 (23.6) 47/309 (15.2) 29/275 (10.6) 26/217 (12.0) 5/154 (3.3) 0/116 (0.0)
Non- vaccine- type 
pneumococcal carriage 
prevalence*, n/N (%)
70 (20.3) 67 (21.7) 54 (19.6) 47 (21.7) 27 (17.5) 37 (31.9)
Percentage of lytA 
positive samples, 
serotype unknown†, n/N 
(%)
15/156 (9.6) 12/117 (10.3) 11/89 (12.4) 12/81 (14.8) 10/42 (23.8) 10/47 (21.3)
Percentage of 
pneumococcal single- 
serotype samples with 
at least one AMR gene, 
n/N (%)
95/127 (74.8) 61/86 (70.9) 49/66 (74.2) 47/57 (82.5) 22/28 (78.6) 19/30 (63.3)
*Pneumococcal carriage was defined as detection of any pneumococcus, including samples that were lytA positive and serotype 
unknown. However, lytA positive samples with an unknown serotype were excluded from VT and NVT carriage prevalence estimates.
†Serotypes were either unknown due to the sample being culture negative (n=71) or unable to be serotyped due to repeated technical 
difficulties with the DNA extraction (n=1)).
Lao PDR, Lao People’s Democratic Republic.
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(58%–75% coverage) was sufficient to induce substantial 
indirect effects on VT carriage.11 12 Previous studies have 
demonstrated a relationship between vaccine coverage 
and indirect effects, including a meta- analysis of studies 
from middle and high- income countries that reported 
a 5% decline in pneumococcal disease (95% credible 
interval 2%–11%) for each 10% increase in coverage.4 34
Our findings also provide the first estimates of VE 
against VT carriage (ie, direct effects) for PCV13 in Asia 
among children 2–59 months of age, adding support to a 
previous community carriage study from Lao PDR which 
demonstrated a 23% reduction in VT carriage following 
PCV introduction among 12–23 month old children.33 
Importantly, both estimates accord with VE estimates 
against a disease outcome in Lao PDR: among the same 
cohort as this study, we found an adjusted PCV13 effec-
tiveness of 37% against hypoxic pneumonia among chil-
dren under five.35 A study from Brazil reported a similar 
VE with three primary doses of PCV13 at 44.0% (14.2%–
63.5%) against VT carriage among children 7–11 months 
of age,36 while a study from Israel found a VE of 62% 
(95% CI 33% to 83%) against PCV13 carriage among 
children 25–59 months of age.37 Our results were also 
lower than estimates of VE for PCV13 from modelling 
in Malawi, at 66.87% (95% CI 50.49% to 82.26%).38 The 
differing estimates may relate to the timing of assessment 
after vaccine is administered to each child (ie, waning 
direct effects), since a meta- regression of original efficacy 
results from PCV7 trials reported VEs ranging from 62% 
(95% CI 52% to 72%) 4 months after vaccination to 42% 
(95% CI 19% to 54%) 5 years after vaccination.39
At 5 years following PCV introduction, VTs were no 
longer detected among a total of 116 samples—indicating 
Figure 2 Monthly adjusted prevalence of vaccine- type 
carriage (7- month rolling intervals), adjusted by age group, 
among children 2–59 months of age admitted with acute 
respiratory infection, by PCV13 status, Vientiane, Lao PDR, 
December 2013–December 2019. Lao PDR; Lao People’s 
Democratic Republic; PCV; pneumococcal conjugate 
vaccine.
Figure 3 Map of 13- valent PCV13 coverage among children under 5 years of age by village, Vientiane Capital*, Lao PDR, 
2014–2017; *Excluding Sisattanak district; data from 2018 was excluded due to small numbers of villages. Lao PDR; Lao 
People’s Democratic Republic; PCV; pneumococcal conjugate vaccine.
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elimination or near- elimination of VTs in Lao PDR. This 
is consistent with high- income countries, such as the USA 
and England, which observed declines of VT carriage to 
less than 5% at 8 and 6 years following vaccine introduc-
tion.40 41However, we recommend continued surveillance 
to determine whether this finding is sustained, especially 
since enrolment declined overtime.
Our carriage surveillance offers a novel approach to 
monitor VT carriage in resource- limited settings.10 In addi-
tion to demonstrating declines in VT carriage among both 
vaccinated and under- vaccinated participants, our carriage 
surveillance indicates that pneumococcal carriage in Lao 
PDR may be seasonal. Previous studies have also demon-
strated variations in pneumococcal carriage prevalence by 
season in a range of settings.42 43 Carriage surveillance can 
help identify when VTs are under control, and therefore a 
1+1 schedule switch can be considered, as well as continue 
to monitor VT carriage after any changes to the vaccination 
programme. This study design has both advantages and 
disadvantages. Compared with recruiting healthy children 
from the community, children in hospitals are an accessible 
population which is more feasible to sample in low- resource 
settings. However in this patient population, the use of antibi-
otics can reduce detection of NP pneumococcal carriage or 
select for carriage of antibiotic resistant strains of particular 
serotypes.29 We have shown that, despite high levels of anti-
biotic use in our study cohort, 87.4% of lytA positive samples 
were able to be cultured for molecular serotyping. The 
percentages of culture- positive samples were similar by vacci-
nation status and remained consistent over time, indicating 
that prior antibiotic use is unlikely to be a major confounder. 
The AMR prevalence in our sample (74.4%) was similar to 
community carriage surveys conducted in Lao PDR over a 
similar period (70.8%), suggesting that the pneumococcal 
epidemiology in our hospitalised cohort reflects community 
trends.33 Similarly, our estimates of overall carriage and VT 
carriage prevalence from 2014 were also comparable to these 
survey estimates (14.3% overall and 6.5% VT carriage preva-
lence among infants (5–8 weeks); 55.8% overall and 32.9% 
VT carriage prevalence among children (12–23 months)).19 
Therefore, we suggest that hospital- based surveillance can 
provide useful indication of pneumococcal trends in the 
community, although we anticipate that our results are 
more reflective of pneumococcal serotypes causing disease.29 
Table 3 Vaccine- type pneumococcal carriage by quartile of village 13- valent pneumococcal conjugate vaccine (PCV13) 
coverage, Lao PDR, December 2013–June 2018*
Vaccine- type pneumococcal carriage
Levels of PCV13 coverage All children n/N (%) Vaccinated children n/N (%) Undervaccinated children n/N (%)
<25% 101/500 (20.2) 36/243 (14.8) 65/257 (25.3)
25%–50% 23/212 (10.9) 13/139 (9.3) 10/73 (13.7)
50%–75% 12/85 (14.1) 8/65 (12.3) 4/20 (20.0)
>75% 3/48 (6.3) 3/37 (8.1) 0/11 (0.0)
*Includes all participants recruited up to June 2017 and the additional 77 participants enrolled up to June 2018 that resided in villages where 
vaccination data had already been collected.
Lao PDR, Lao People’s Democratic Republic; PCV, pneumococcal conjugate vaccine.
Table 4 Crude and adjusted* ORs of vaccine- type and overall pneumococcal carriage among children under 5, by 
percentage increase in 13- valent pneumococcal conjugate vaccine (PCV13) coverage and individual vaccination status, Lao 
PDR, December 2013–June 2018†; results are shown for complete participant analyses (n=845)
Crude Adjusted*
OR (95% CI) P value OR (95% CI) P value
Vaccine- type (VT) carriage
PCV13 coverage 0.983 (0.972 to 0.994) 0.003 0.989 (0.978 to 1.000) 0.056
PCV13 status 0.520 (0.356 to 0.759) 0.001 0.619 (0.400 to 0.959) 0.032
PCV13 effectiveness (%)‡ 48.0 (34.1 to 64.1) 0.001 38.1 (4.1 to 60.0) 0.032
Overall pneumococcal carriage
PCV13 coverage 0.996 (0.990 to 1.003) 0.255 0.998 (0.991 to 1.004) 0.475
PCV13 status 1.026 (0.778 to 1.356) 0.859 1.094 (0.777 to 1.542) 0.606
PCV13 effectiveness (%)‡ −2.6% (−35.6 to 22.2) 0.859 −9.4 (-54.2 to 22.3) 0.606
*Adjusted by family income, age, season, number of children under 5 in the household and kindergarten attendance.
†Includes all participants recruited up to June 2017 and the additional 77 participants enrolled up to June 2018 that resided in villages where 
vaccination data had already been collected.
‡PCV13 effectiveness against VT carriage was one minus the adjusted OR for the association between VT carriage and individual PCV13 
status and multiplied by 100.
PCV, pneumococcal conjugate vaccine.
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Further research comparing hospital- based and community- 
based carriage studies are required to understand the gener-
alisability of hospital- based surveillance.
A strength of our study is the use of vaccine coverage at 
a village level as an exposure to determine vaccine impacts. 
This is a novel application of methods originally used to eval-
uate cholera vaccines,9 enabling us to determine robust esti-
mates for both direct and indirect effects of PCV13 within the 
same model.44 We also assessed the likelihood of bias, finding 
no association between PCV coverage and overall pneumo-
coccal carriage. Since most studies show that PCV does not 
reduce overall pneumococcal carriage,10 the contrasting 
results, with the presence of an association with VT carriage 
but not overall carriage, support the validity of our findings 
attributing reductions in VT carriage to vaccine coverage 
rather than other confounding factors. Our estimates of 
vaccine coverage were based on administrative data, which 
have previously been reported to overestimate coverage 
compared with survey data.45 46 There may also be variation 
in data quality by health centre, errors in transcribing hand- 
written registers and mismatches in numerators and denom-
inators for village- level estimates.47 However, our coverage 
results among children 12–23 months of age (59.7%, online 
supplemental table 4) were very similar to those from the Lao 
Social Indicator Survey from 2017 which found that coverage 
of two doses of PCV was 53% among children 12–23 months 
of age in Vientiane Capital, our study site.48
A limitation of our study is that we did not assess carriage 
in adults and the elderly, populations which have been the 
greatest beneficiary of indirect effects in high- income coun-
tries. However, we expect that the indirect effects seen in 
children can be extrapolated to adults, since multiple studies 
from other settings with low pneumococcal carriage prev-
alence identify children under 5 years of age as the main 
drivers of transmission.20 49 50 Individual vaccination status was 
missing for 15% of our participants, however, comparison of 
participant characteristics in table 1 suggests no systematic 
differences between groups included and excluded from 
the primary analyses. Lastly, within our study period, median 
vaccine coverage reached only 37.5% (IQR 24.1%–56.4)% 
among all children under 5 years of age. Furthermore, there 
were fewer participants, including participants carrying VTs, 
recruited in 2018 and 2019, as coverage increased. Therefore, 
we have only estimated indirect effects up to 60% coverage, 
although we expect continued increases in indirect effects as 
coverage increases.
The degree of indirect effects has two important policy 
implications. First, the cost- effectiveness of the vaccine greatly 
improves when the indirect effects are present and taken into 
account, helping policy makers to justify the public funding 
of the vaccine.51 Second, the control of VT transmission is a 
necessary prerequisite for the use of 1+1 schedules, which 
are currently under investigation, and has the potential to 
maintain vaccine impacts through indirect effects while 
reducing programme costs.8 The generation of indirect 
effects is an important component of achieving control of 
VTs. Furthermore the success of this schedule relies on the 
ongoing generation of indirect effects to protect children 
under the age of 12 months who do not have sufficient indi-
vidual immunity to protect them from disease.52
Our results provide insight into the direct and indirect 
effects of PCV in Lao PDR and have important implications 
Figure 4 Predicted probability of vaccine- type carriage (top row) and overall pneumococcal carriage (bottom row) by level 
of 13- valent pneumococcal conjugate vaccine (PCV13) coverage, Lao PDR, 2013–2018; figures on the left are unadjusted 
while figures on the right are adjusted by vaccination status, family income, age, season, number of children under 5 in the 
household and kindergarten attendance. Lao PDR; Lao People’s Democratic Republic.
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for other countries in the region, many of which have yet to 
introduce PCV into routine childhood immunisation sched-
ules. Importantly our results demonstrate that near elimina-
tion of VT carriage is possible in LMICs, and therefore, the 
introduction of cost- saving 1+1 schedules should be consid-
ered and evaluated for such settings. However, given the 
heterogeneity in vaccine coverage, it would be important to 
consider the possibility of continued pockets of VT pneumo-
coccal transmission within areas of low vaccine coverage. We 
recommend continued pneumococcal carriage surveillance 
to ensure VTs remain under control among populations 
most at risk of disease.
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Health centre data collection 
Data from health centre immunisation register books were collected to determine the numerator for PCV13 
coverage in each village. Study staff first generated a list of villages in which enrolled cases resided and 
determined the health centre that served each village. They then planned a schedule of health centre visits and 
prepared letters to each health centre detailing our study, the purpose of the visit, the month of the visit and 
contact details.  
At each health centre, with the exception Sisattanak district, immunisations were recorded in register books 
which contain line-listed data of each child residing in the village and the dates that vaccinations were 
administered for that child. As with the cases, we defined a child as vaccinated if they had received two or 
more PCV13 doses at less than 12 months of age, or at least one dose at or after 12 months of age. In 
Sisattanak district, immunisations were recorded on sheets of paper by date of administration, with a new 
sheet for each day. We therefore excluded Sisattanak district, which has a population of 11 069 children under 
five years, from our analysis as we were unable to determine how many children were vaccinated according to 
our study definitions. 
At each health centre visit, study staff took photographs of each page of each immunisation register book to 
facilitate transcription of hand-written data into a study database following the visit. To ensure accuracy of 
data transcription, study staff confirmed with health centre staff when PCV was introduced at the health centre 
and how PCV data was recorded. If the health centre transitioned between register books during the study 
period, staff clarified whether entries were transferred between old and new immunisation register books.  
For each village, study staff assessed data quality according to three key measures:  
1. Were PCVs clearly marked? – in earlier iterations of data registration books, there may not be a 
column a separate column to record PCV13 so health centre staff recorded doses of PCV13 in various 
ways  
2. Were PCV13 dates legible? 
3. Is there evidence of missing registration books? 
Health centre data were categorised as low quality if PC13 were not clearly marked, or PCV dates were 
illegible or there was evidence of missing registration books.  
Study staff transcribed the following data from register books into a study database: child’s name, date of 
birth, village, and the date PCV13 was administered. To ensure that children were not entered into the 
database twice, study staff reviewed books for duplicate entries and crossed-out and highlighted records for 
entry. Where date of birth was not documented, dates of hepatitis B or BCG vaccination were used as 
surrogates as these vaccines are given at birth. Data were initially entered into an EpiData database and 
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potential confounders including both measured and unmeasured variables. Based on this diagram, we 
identified that adjusting for age, season, other children in the household, socioeconomic status and 
kindergarten attendance is sufficient to block biasing pathways. There may be time trends associated with risk 
of VT carriage, however since PCV coverage and time are collinear for the duration of our study, and we do 
not have any pre-PCV data, we were not able to include time in our analyses.  
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Supplementary table 1: Participant characteristics by year of enrolment, Lao PDR, December 2013 – June 2019 
 2013-4 2015 2016 2017 2018 2019 
Median age in months, (IQR)  14.0 (7.0-23.0) 15.0 (8.0-25.0) 16.0 (9.0-26.0) 15.0 (8.0-27.0) 17.5 (9.0-28.0) 17.0 (9.0-27.0) 
Age group, n (%)       
     2-11m 150 (41.8%) 131 (40.8%) 109 (38.1%) 95 (41.5%) 57 (34.8%) 48 (38.1%) 
     12-35m 121 (33.7%) 105 (32.7%) 94 (32.9%) 60 (26.2%) 50 (30.5%) 36 (28.6%) 
     36-59m 88 (24.5%) 85 (26.5%) 83 (29.0%) 74 (32.3%) 57 (34.8%) 42 (33.3%) 
Male, n (%)   205 (57.1%) 181 (56.4%) 159 (55.6%) 128 (55.9%) 85 (51.8%) 67 (53.2%) 
Wet season, n (%)   210 (58.5%) 124 (38.6%) 168 (58.7%) 105 (45.9%) 84 (51.2%) 57 (45.2%) 
Urban§, n (%) (N=1482) 346 (96.4%) 301 (94.1%) 268 (94.4%) 220 (96.1%) 158 (96.3%) 120 (95.2%) 
Kindergarten attendance, n (%) 
(N=1477)  
63 (17.8%) 62 (19.5%) 75 (26.2%) 52 (22.7%) 40 (24.4%) 37 (29.4%) 
Median number of other children 
<5y in house, (IQR) (N=1476) 
1.0 (1.0-2.0) 1.0 (1.0-2.0) 1.0 (1.0-2.0) 1.0 (1.0-2.0) 1.0 (1.0-2.0) 1.0 (1.0-2.0) 
Family income per month, n (%) 
(N=1476) 
      
     < =250,000 kip 64 (18.1%) 7 (2.2%) 3 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
     250,001 – 1,000,000 kip 162 (45.8%) 99 (31.0%) 37 (12.9%) 1 (0.4%) 1 (0.6%) 1 (0.8%) 
     1,000,001 – 3,000,000 kip 93 (26.3%) 163 (51.1%) 140 (49.0%) 93 (41.0%) 53 (32.3%) 49 (38.9%) 
     3,000,001 – 5,000,000 kip 23 (6.5%) 43 (13.5%) 87 (30.4%) 97 (42.7%) 58 (35.4%) 72 (57.1%) 
     >5,000,000 kip 12 (3.4%) 7 (2.2%) 19 (6.6%) 36 (15.9%) 52 (31.7%) 4 (3.2%) 
Maternal education (completion of 
primary school), n (%) (N=1345) 
291 (82.4%) 251 (79.9%) 232 (82.0%) 59 (54.1%) 139 (86.9%) 111 (88.1%) 
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Piped water source, n (%) 
(N=1483)  
201 (56.1%) 177 (55.3%) 173 (60.5%) 127 (55.5%) 94 (57.3%) 71 (56.3%) 
Wood or charcoal used for cooking 
fuel, n (%) (N=1178)  
5 (9.3%) 300 (93.8%) 257 (90.2%) 211 (92.1%) 147 (89.6%) 109 (86.5%) 
Smoker in the house, n (%) 
(N=1471)  
151 (43.4%) 121 (37.9%) 115 (40.4%) 122 (53.3%) 76 (46.3%) 47 (37.3%) 
Pneumonia categories, n (%)¶ 
(N=1467) 
      
     Acute respiratory infection  134 (37.3%) 130 (41.7%) 113 (40.1%) 94 (41.8%) 54 (33.1%) 49 (38.9%) 
     Pneumonia (not severe) 88 (24.5%) 98 (31.4%) 76 (27.0%) 62 (27.6%) 51 (31.3%) 42 (33.3%) 
     Severe pneumonia 137 (38.2%) 84 (26.9%) 93 (33.0%) 69 (30.7%) 58 (35.6%) 35 (27.8%) 
Pre-admission antibiotics**, n (%) 
(N=1432)  
225 (64.1%) 162 (51.8%) 114 (41.5%) 112 (53.8%) 91 (56.9%) 62 (49.6%) 
Received antibiotics in hospital, n 
(%) (N=1453)  
311 (87.1%) 272 (86.9%) 246 (88.8%) 193 (86.5%) 140 (87.0%) 104 (85.2%) 
Comorbidities, n (%) 33 (9.2%) 7 (2.2%) 6 (2.1%) 42 (18.3%) 50 (30.5%) 27 (21.4%) 
Vaccination status, n(%) (N=1249)       
     Under-vaccinated 223 (62.1%) 113 (35.2%) 73 (25.5%) 36 (15.7%) 33 (20.1%) 14 (11.1%) 
     Vaccinated 107 (29.8%) 162 (50.5%) 155 (54.2%) 145 (63.3%) 109 (66.5%) 79 (62.7%) 
     Missing 29 (8.1%) 46 (14.3%) 58 (20.3%) 48 (21.0%) 22 (13.4%) 33 (26.2%) 
*N=1485 unless otherwise specified in the first column; § Categorised as urban if the village falls within Vientiane Capital; ¶ WHO 2013 definition; **Parent 
report 
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Pneumococcal serotypes by year 
 
Supplementary figure 2: Pneumococcal serotypes by year, Lao PDR, 2014-2019 
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2018 (N†=7) 49.7 (26.1-74.0) 43.3 (26.1-49.7) 70.0 (39.5-82.1) 
* Median coverage and IQR among all villages for which we have collected PCV13 coverage data † Number 
of villages 
Supplementary table 3: Median* village 13-valent pneumococcal conjugate vaccine (PCV13) coverage 
calculated among children 12-23 months of age by year and location, Lao PDR, 2014-2018 







2014 0.0 (0.0-11.5) 5.9 (0.0-20.0) 0.0 (0.0-0.0) 
2015 40.3 (6.7-77.6) 48.8 (22.9-88.0) 22.2 (0.0-50.0) 
2016 (N†=553) 66.3 (34.5-97.1) 67.6 (35.9-98.7) 59.1 (30.3-90.5) 
2017 (N†=550) 62.5 (37.8-94.8) 59.7 (28.6-88.9) 71.0 (44.7-102.8) 
2018 (N†=7) 50.0 (11.5-82.1) 50.0 (37.7-82.1) 44.2 (5.8-95.4) 
* Median coverage and IQR among all villages for which we have collected PCV13 coverage data † Number 
of villages 
Supplementary table 4: Crude and adjusted* odds ratios of vaccine-type pneumococcal carriage among 
children under five, by percent increase in 13-valent pneumococcal conjugate vaccine (PCV13) coverage and 
individual vaccination status, Vientiane, Lao PDR, December 2013 – June 2018 
 Crude Adjusted* 
OR (95% CI) p-value OR (95% CI) p-value 
Excluding cases from villages with missing vaccination books (included cases, N=673) 
PCV13 coverage 0.985(0.973-0.997) 0.016 0.993 (0.981-1.004) 0.219 
PCV13 status 0.520 (0.356-0.759) 0.001 0.583 (0.358-0.949) 0.030 
PCV13 effectiveness (%)† 48.0 (24.1-64.4) 0.001 41.7 (5.1-64.2) 0.030 
Excluding cases from villages with poor quality vaccination data (included cases, N=67) 
PCV13 coverage 0.984 (0.0.954-1.017) 0.344 0.990 (0.962-1.020) 0.519 
PCV13 status 0.520 (0.0.356-0.758) 0.001 0.220 (0.036-1.322) 0.098 
PCV13 effectiveness (%)† 48.0 (24.2-64.4) 0.001 78.0 (-32.2-96.4) 0.098 
* adjusted by family income, age, season, number of children under five in the household and kindergarten 
attendance, †PCV13 effectiveness against VT carriage was one minus the adjusted odds ratio for the 
association between VT carriage and individual PCV13 status and multiplied by 100 
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